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Finally, using an inducible ROR reporter system, we 
showed that 11-HSD1 and 11-HSD2 controlled ROR 
activity.  These findings revealed a novel glucocorticoid-
independent prereceptor regulation mechanism by 11-HSDs 
that warrants further investigation.—Beck, K. R., S. G. 
Inderbinen, S. Kanagaratnam, D. V. Kratschmar, A. M. Jetten, 
H. Yamaguchi, and A. Odermatt. 11-Hydroxysteroid dehy-
drogenases control access of 7,27-dihydroxycholesterol 
to retinoid-related orphan receptor . J. Lipid Res. 2019. 
60: 1535–1546.
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Oxysterols originate from cholesterol or cholesterol pre-
cursors and previously were mainly considered intermedi-
ates of bile acid and steroid hormone biosynthetic pathways. 
They display additional oxygen functionalities in the ring 
system and/or at the side chain of cholesterol, deriving 
through either enzymatic reactions and/or radical pro-
cesses (1). Oxysterols are involved in several physiological 
processes including cholesterol, carbohydrate, and lipid 
homeostasis, immune system regulation, and neuronal 
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development. Furthermore, recent research emphasized 
their role as bioactive lipids, contributing to the progres-
sion of various pathologies, such as neurodegenerative dis-
eases, atherosclerosis, and cancer [reviewed in (2–6)]. 
Nevertheless, the metabolic pathways leading to the differ-
ent oxysterols remain insufficiently understood and their 
biosynthetic origins need to be elucidated.
7-Ketocholesterol (7kC) is one of the most extensively 
studied oxysterols and particularly known for its pro-in-
flammatory and cytotoxic properties [reviewed in (1, 7, 
8)], and it was recently reported to be associated with car-
diovascular outcomes and total mortality in patients with 
coronary artery disease (9). However, it remains unclear 
whether 7kC itself or its metabolites caused these biologi-
cal effects. In situ, 7kC is mainly generated by autoxidation 
of cholesterol during conditions of oxidative stress. In con-
trast to the low abundance of oxysterols in the circulation 
compared with cholesterol, 7kC is present at levels up to 
10 M in macrophage-derived foam cells in atherosclerotic 
lesions and in lenses of patients with cataract (10–12). In 
macrophages and in the retinal pigment epithelium, sterol 
27-hydroxylase (CYP27A1) was found to convert 7kC to 
7-keto,27-hydroxycholesterol (7k27OHC) by (13, 14). This 
metabolic step is ablated in macrophages derived from pa-
tients suffering from cerebrotendinous xanthomatosis, 
bearing a defect in the gene encoding CYP27A1 (13). 
These patients have normal circulating cholesterol, but in-
creased 7kC levels, and are prone to the development of 
premature atherosclerosis (15).
Hepatic conversion of dietary 7kC to 7k27OHC is evident 
because the mitochondrial CYP27A1 is the first enzyme in-
volved in the alternative biosynthesis pathway of bile acids 
in the liver (16, 17). However, a study with mice bearing a 
homozygous null mutation in the Cyp27 gene showed rapid 
and extensive hepatic 7kC metabolism, indicating the in-
volvement of another enzyme (18). This enzyme was later 
proposed to be 11-hydroxysteroid dehydrogenase type 
1 (11-HSD1), stereo-specifically converting 7kC into 
7-hydroxycholesterol (7OHC) in humans, rats, and mice 
(19–21). Data from transgenic 11-hsd1-deficient mice 
exhibiting an increased 7kC to 7OHC ratio in liver tissue 
samples further supported these results (22).
The role of 11-HSD1, well-known for the local conver-
sion of glucocorticoids from inactive to active, in oxysterol 
metabolism and atherosclerotic plaque progression has 
been addressed by several studies [reviewed in (23)]. Inter-
estingly, no direct accumulation of 7kC could be detected 
in the arterial wall of hsd11b1/ mice (24), and a loss of 
11-HSD1 function was rather associated with an athero-
protective and beneficial metabolic profile (25–27). 
Whether the observed favorable effects of diminished 11-
HSD1 activity are due to decreased intracellular levels of 
active glucocorticoids, or whether they are glucocorticoid-
independent, remained unclear. This raised the hypothesis 
that 7kC acts as a precursor molecule requiring further 
downstream processing by another enzyme to exert its 
activity. Despite the extensive research focusing on the effects 
of 7kC and 7OHC, only a weak interaction of 7kC with 
the arylhydrocarbon receptor and no cognate high-affinity 
receptors have been identified for 7kC and 7OHC so 
far (28). However, for the sidechain-oxidized or the dihy-
droxylated oxysterols, such as 7,27-dihydroxycholesterol 
(727OHC), several targets have been described [reviewed 
in (2)]. A recent study on Smoothened (Smo)-activating 
oxysterols suggested the conversion of 7OHC to 7kC by 
11-HSD2, which required further metabolism by CYP27A1 
to 7k27OHC in order to regulate Smo activity (29, 30). The 
enzymatic control of Smo by 11-HSDs remains unclear, as 
both 7k27OHC and 727OHC were reported to promote 
Smo activity. Importantly, another receptor, retinoid- 
related orphan receptor  (ROR), was recently found to 
be activated by 727OHC, whereas 7k27OHC did not stim-
ulate full-length ROR activity in reporter gene assays (31). 
Nevertheless, a potential role for 11-HSDs in the cell- 
specific metabolic availability of 727OHC and 7k27OHC, as 
they exert for glucocorticoids, has not yet been addressed. 
Thus, we investigated to determine whether 11-HSDs are 
involved in the metabolism of 7-oxygenated 27OHCs and 
thereby could control the regulation of target receptors 
such as ROR.
MATERIALS AND METHODS
Chemicals and reagents
7k27OHC, 727OHC, 727OHC, and 727OHC-d6 were 
obtained from Avanti Polar Lipids, Inc. (Alabaster, AL), [1,2-3H]
cortisone, [1,2,6,7-3H]cortisol, and [1,2,6,7-3H] corticosterone 
from American Radiolabeled Chemicals (St. Louis, MO), and all 
other chemicals from Sigma-Aldrich (Buchs, Switzerland) of the 
highest grade available. Cell culture media were purchased from 
Sigma-Aldrich and Invitrogen (Carlsbad, CA) and FBS approved 
for use with the Tet-on system from Clontech (Mountain View, 
CA). UHPLC-grade purity methanol, acetonitrile, and formic acid 
were from Biosolve (Dieuze, France). 5H-1,2,4-triazolo(4,3-a)
azepine,6,7,8,9-tetrahydro-3-tricyclo(3-3-1-13-7)dec-1-yl [T0504; 
also known as Merck-544 (25)] was purchased from Enamine 
(Kiev, Ukraine).
Cell culture
HEK-293 cells and human SW-620 colon carcinoma cells were 
obtained from ATCC (Manassas, VA) and cultured in DMEM sup-
plemented with 10% FBS, 4.5 g/l glucose, 100 U/ml penicillin/
streptomycin, 2 mM l-glutamine, 10 mM HEPES (pH 7.4), and 
10% MEM nonessential amino acid solution. Doxycycline-inducible 
ROR stable Chinese hamster ovary (CHO) Tet-on cells were cul-
tured in F12 medium containing 10% FBS approved for use with 
the Tet-on system and 100 U/ml penicillin/streptomycin (32, 33). 
Cells were regularly tested for the absence of mycoplasma.
11-HSD-dependent metabolism of 7-oxygenated 
27OHCs in intact cells
Fifty thousand stably transfected HEK-293 cells expressing 
either 11-HSD2 [clone AT8 (34)] or 11-HSD1 and hexose-
6-phosphate dehydrogenase (H6PDH) [clone HHH7 (35)] were 
seeded in poly-l-lysine-coated 96-well plates and incubated for 24 h. 
H6PDH provides the cofactor NADPH and is required for an 
efficient oxoreduction reaction by 11-HSD1 (36). The medium 
was changed to steroid- and phenol red-free DMEM (DMEM SF) 
for another 2 h and the cells were then treated with 1 M of 
7k27OHC in the presence or absence of 1 M of T0504 (to inhibit 
11-HSD1) or 0.5 M of 727OHC or 727OHC in the presence 
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or absence of 5 M of glycyrrhetinic acid (GA) (to inhibit 11-
HSD2). Metabolic conversion was determined after 0.5 h for 11-
HSD2 and after 1 h for 11-HSD1.
SW-620 cells (500,000 cells/well) were seeded in 24-well plates 
and incubated for 24 h. The culture medium was replaced by 
DMEM SF containing 1 M of 7OHC in the presence or absence 
of 10 M of GA for 3.5 h or 7 h.
Ice-cold acetonitrile:isopropanol (7:3, v/v) mixture contain-
ing either 100 nM deuterium-labeled 727OHC or corticoste-
rone as internal standards were used to extract oxysterols from 
cell culture supernatants. Additionally, 1.5% (v/v) of a standard 
solution of the antioxidant butylated hydroxytoluene (BHT) and 
the peroxide reducing agent triphenylphosphine (TPP) (10 mg 
BHT and 25 mg TPP in 10 ml ethanol) was added (37). In experi-
ments with SW-620 cells, oxysterols were extracted from cell su-
pernatants and cells. The samples were incubated for 30 min at 
4°C and 700 rotations per minute, centrifuged (16,000 g, 10 min, 
4°C), and the supernatant evaporated to dryness under nitrogen 
to minimize oxidation from atmospheric oxygen. After reconsti-
tution in 50 l of methanol:ultra-pure water (1:1, v/v), the sam-
ples were again centrifuged (16,000 g, 10 min, 4°C) and the 
supernatants analyzed. Data (mean ± SD) were obtained from 
three independent experiments.
11-HSD enzyme kinetic measurements
Preparation of microsomes. Microsomes were prepared as de-
scribed earlier with minor modifications (38). Briefly, HEK-293 
cells stably expressing human 11-HSD1 and H6PDH were cul-
tured until they reached confluence. Then, they were washed 
with ice-cold PBS and resuspended to a final concentration of 
2 × 107 cells/ml in ice-cold buffer A [50 mM Tris (pH 7.5), 1 mM 
EDTA, 100 mM NaCl]. Typically, 6 ml of this suspension were 
prepared, corresponding to 1.2 × 108 cells. Following homogeni-
zation with 20 strokes in a glass potter on ice, the preparation was 
sonicated and centrifuged (9.000 g, 4°C for 30 min). The superna-
tant was removed and subjected to ultracentrifugation at 105,000 g, 
4°C for 70 min. The obtained pellet was resuspended in buffer B 
[20 mM Tris (pH 7.5), 1 mM EDTA, 10% glycerol] and the 
ultracentrifugation step repeated. The microsomal fraction was 
again resuspended in buffer B and the total protein concentra-
tion determined using BCA assay (39). The microsomes were 
immediately frozen on dry ice and stored at 80°C.
Determination of apparent KM and Vmax values. Microsomes (1–20 
g) expressing 11-HSD1 and H6PDH were incubated for 20 min 
with 1 mM of NADPH, 2 mM of glucose-6-phosphate, 0.1 units of 
glucose-6-phosphate dehydrogenase (from Saccharomyces cerevi-
siae), and different concentrations (62.5–2,000 nM) of 7k27OHC, 
adapted to a total assay volume of 50 l with TS2 buffer [100 mM 
NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM MgCl2, 250 mM sucrose, 
20 mM Tris/HCl (pH 7.4)]. Oxysterols were extracted by mixing 
the samples with ice-cold ethyl acetate containing 100 nM deute-
rium-labeled 727OHC as internal standard and 1.5% (v/v) BHT/
TPP solution as antioxidant. The samples were then incubated for 
15 min at 4°C on a rotating mixer, shortly centrifuged, and the 
upper ethyl acetate phase transferred into a new tube. The extrac-
tion step was repeated and the ethyl acetate phases combined and 
evaporated to dryness under nitrogen. After reconstitution in 50 
l of methanol:ultra-pure water (1:1, v/v), the samples were centri-
fuged (4°C, 16,000 g for 10 min) and analyzed by UHPLC-MS/MS.
For 11-HSD2 activity measurements, 0.8 g of HEK-293 cell 
lysate stably expressing 11-HSD2 was incubated with different 
concentrations (50–800 nM) of 727OHC and 500 M of NAD+ 
for 10–30 min. Oxysterols were extracted as described in the 11-
HSD-dependent metabolism of 7-oxygenated 27OHCs in intact 
cells section.
The substrate conversion was kept below 30% in all reactions. 
Apparent kinetic parameters (KM and Vmax) were determined by 
nonlinear regression and under the assumption of Michaelis-
Menten kinetics. Data (mean ± SD) were obtained from three in-
dependent experiments.
Sterol measurement by UHPLC-MS/MS
An Agilent 1290 Infinity UHPLC binary solvent delivery system 
including a temperature controlled autosampler and a column 
oven coupled to an Agilent 6490 triple quadrupole mass spectrom-
eter with a jet stream electrospray ionization interface (AJS-ESI) 
(Agilent Technologies) was used to analyze oxysterols. A reversed-
phase column (ACQUITY UPLC BEH C18, 1.7 m, 2.1 × 150 mm; 
Waters, Wexford, Ireland) heated to 65 ± 0.8°C was applied for 
analyte separation. The flow-rate was 0.5 ml with solvent A [water/
acetonitrile/formic acid (95/5/0.1, v/v/v)] and solvent B 
[water/acetonitrile/formic acid (5/95/0.1, v/v/v)]. The eluent 
gradient was set as follows: 0–4.5 min 45–97% B, 4.5–7 min 80% B 
(washout), and 7–9 min 45% B (column re-equilibration). 
Methanol/water (75/25, v/v) was used as needle and needle-seat 
flushing solvent for 10 s after sample aspiration. The samples 
were stored in the autosampler at 4°C until analysis.
Analyte fragmentation was directed in the positive ion mode 
for multiple reaction monitoring and source conditions defined 
by use of the integrated compound- and source-optimizer soft-
ware module (Agilent Technologies; B.07.01). Multiple reaction 
monitoring transitions were defined as follows: 7k27OHC (m/z 
417.3 → 417.3; retention time = 3.59 min), 727OHC (m/z 383.3 
→ 159.0; retention time = 3.45 min), 727OHC (m/z 383.3 → 
383.3 and m/z 159.0; retention time = 3.57 min), 727OHC-d6 
(m/z 407.38 → 159.1 and m/z 389.1; retention time = 3.42 min). 
Separation and retention time of 7k27OHC, 727OHC, and 
727OHC are shown in supplemental Fig. S1. Source parameters 
were as follows: gas temperature 290°C, gas flow 14 l/min, sheath 
gas temperature 300°C, sheath gas flow 11 l/min, nozzle voltage 
1,500 V, capillary voltage 3,000 V, cell accelerator voltage 4 V, frag-
mentation voltage 380 V, and nebulizer 20 psi.
For data acquisition and analysis, MassHunter Workstation 
Acquisition Software Version 07.01 SP1 and MassHunter Work-
station Software Quantitative Analysis Version B.07.00/Build 
7.0457.0, respectively (Agilent Technologies), were used.
Inhibition of 11-HSD-dependent glucocorticoid 
metabolism in cell lysates
11-HSD1 and 11-HSD2 enzyme activities were assessed in 
lysates of HEK-293 cells stably expressing the respective enzyme as 
reported earlier (40). Briefly, 11-HSD1-dependent oxoreduc-
tase activity was determined by the incubation of lysates with 
200 nM of radiolabeled cortisone, 500 M of NADPH, and the test 
substance or vehicle for 10 min at 37°C. 11-HSD2-dependent 
oxidation of cortisol was measured instead by the addition of 50 nM 
of radiolabeled cortisol and 500 M of NAD+. The enzymatic reac-
tion was stopped by introducing an excess amount of unlabeled 
cortisone and cortisol (1:1, 2 mM unlabeled each, in methanol). 
Cortisone and cortisol were separated using TLC and a chloro-
form and methanol (9:1, v/v) mixture. The bands were detected 
under UV light, scraped off the plate, and metabolism of the 
radiolabeled substrate was then evaluated by scintillation counting 
and the substrate conversion determined and compared with the 
control sample. Data (mean ± SD) were normalized to the control 
(DMSO) sample and obtained from at least three independent 
experiments.
11-hsd2 activity in mouse kidney homogenates
The determination of 11-hsd2 activity in mouse kidney 
homogenates was conducted as described earlier (41). Briefly, 
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for homogenate preparation, kidneys from adult male mice 
(C57BL6) were snap-frozen and sonicated in homogenization 
buffer [250 mM sucrose, 10 mM HEPES (pH 7.4); 900 l for 100 
mg of tissue]. Then, the homogenate was centrifuged (2,000 g, 
4°C for 10 min) and the total protein concentration determined. 
The enzymatic reaction was assessed using 0.075 mg/ml total pro-
tein of the kidney homogenate in incubation buffer [300 mM 
NaCl, 20 mM Tris/HCl, 1 mM EDTA, 10% glycerol (pH 7.7)], 
different concentrations of oxysterols, 50 nM of corticosterone 
(containing 50 nCi [1,2,6,7-3H] corticosterone), and 500 M 
NAD+ at 37°C for 20 min. Corticosterone and 11-dehydrocortico-
sterone were separated using TLC. Substrate conversion was 
determined by scintillation counting. Data (mean ± SD) were 
normalized to vehicle control (DMSO) and obtained from at least 
three independent experiments.
Mineralocorticoid receptor reporter gene assay
HEK-293 cells stably expressing 11-HSD2 (AT8 cells) were 
seeded (100,000 cells per well) in poly-l-lysine-coated 24-well 
plates and incubated for 24 h. Then, the cells were transiently 
transfected with the mineralocorticoid receptor (MR) (300 ng/
well), a TAT3-TATA luciferase reporter (450 ng/well), and a 
pCMV-lacZ -galactosidase transfection control (25 ng/well) us-
ing the calcium phosphate precipitation method. At 6 h post-
transfection, the cells were washed with DMEM and incubated for 
another 18 h before replacing the medium with cDMEM. The 
cells were cultured for another 2 h at 37°C. The medium was then 
again replaced with fresh cDMEM containing 50 nM cortisol in 
the presence or absence of different concentrations (78–2,500 
nM) of 7k27OHC and 727OHC, and incubated for 24 h. The 
cells were lysed with Tropix lysis solution (Applied Biosystems, 
Foster City, CA) containing 0.5 mM of dithiothreitol and frozen 
at 80°C for at least 20 min. Luciferase activity was measured by 
the addition of D-luciferin-firefly substrate solution [0.47 mM 
D-luciferin, 53 mM ATP, 0.27 mM CoA, 0.13 mM EDTA, 33.3 mM 
dithiothreitol, 8 mM MgSO4, 20 mM tricine (pH 7.8)]. -
Galactosidase activity was determined using the Tropix kit. Data 
(mean ± SD) were normalized to the control (50 nM cortisol) and 
obtained from three independent experiments.
ROR reporter gene assays
Doxycycline-inducible ROR CHO Tet-on cells were trans-
fected with 11-HSD1/H6PDH, 11-HSD2. or pcDNA3 using the 
electroporation method according to the manufacturer’s proto-
col (Neon™ transfection system; Invitrogen). Briefly, the cells 
were resus per well). Three electric pulses of 1,620 V and 10 ms 
were delivered to the cells using a 100 l gold tip. Then, the cells 
(20,000 cells per well) were seeded in 96-well plates using culture 
medium without antibiotics and incubated for 16 h. The medium 
was replaced with medium containing charcoal-dextran stripped 
FBS for 1.5 h before treating the cells with different concentra-
tions of oxysterols. After 6 h, 1.25 M of the inverse agonist 
SR2211 was added to the treatment for another 2 h. To induce 
ROR expression, the cells were additionally subjected to 1 M 
doxycycline for a further 16 h. The cells were lysed in 20 l Tropix 
lysis solution supplemented with 0.5 mM dithiothreitol. ROR-
mediated activation of the luciferase reporter was measured in 10 
l lysate by adding 100 l of D-luciferin-firefly substrate solution. 
Data (mean ± SD) were obtained from at least three independent 
experiments.
Molecular docking calculations
GOLD software (version 5.2, Cambridge Crystallographic Data 
Centre, Cambridge, UK) was applied to identify accurate docking 
poses for oxysterols in the binding sites of 11-HSDs (42). Interac-
tions found between the ligands and the proteins were further 
assessed by the use of LigandScout 3.12 (Inte:Ligand GmbH, 
Vienna, Austria). This software analyzes the interaction patterns 
between the protein and the docked ligand, based on the geomet-
ric distances, angles, and chemical functionalities (43).
For 11-HSD1 docking calculations, the crystal structure with 
the Protein Data Bank entry 2BEL (https://www.rcsb.org/
structure/2BEL) was selected for the human protein and for the 
mouse ortholog the Protein Data Bank entry 1Y5R (https://www.
rcsb.org/structure/1Y5R). The co-crystallized ligands, carbenox-
olone (2BEL) and corticosterone (1Y5R), were extracted from 
the ligand binding sites in order to be redocked and examined to 
determine whether GOLD could restore the original binding ori-
entation. The binding site was defined as spherical space (9 Å, 
respectively 10 Å radius) centered on the hydroxyl group of 
Tyr183 in 2BEL (X = 3.08; Y = 19.19; Z = 13.65) and 1Y5R (X = 
76.88; Y = 49.68; Z = 38.08). The applied settings were validated 
and showed RMSD values of 0.563 for carbenoxolone and 0.683 
for corticosterone.
Two homology models were used for docking calculations for 
human (44) and murine (45) 11-HSD2. The docking settings for 
the human 11-HSD2 binding site were focused on following co-
ordinates X = 20.5; Y = 0.60; Z = 11.38 surrounded by a 12 Å 
sphere. The residues, Arg212 and Ser152 (Ser219 in full-length 
protein), were edited as flexible. The settings for the mouse 11-
hsd2 binding site were centered on the coordinates X = 19.7; 
Y = 1; Z = 10.5 and defined as spherical space with a 10 Å radius. 
The amino acid, Trp276, was set flexible.
RESULTS
11-HSD1-dependent oxoreduction of 7k27OHC
In order to investigate whether 11-HSD1 metabolizes 
7k27OHC, HEK-293 cells stably expressing human 11-
HSD1 and H6PDH were treated with 1 M of 7k27OHC in 
the presence or absence of the specific 11-HSD1 inhibitor, 
T0504. 7k27OHC was stereo-specifically converted to 
727OHC (Fig. 1A, supplemental Fig. S2), with an apparent 
enzyme velocity (Vapp) value of 0.52 ± 0.10 nmol·h
1·mg total 
protein1 compared with a Vapp of 1.59 ± 0.25 nmol·h
1·mg 
Fig. 1. 11-HSD1-dependent metabolism of 7k27OHC in intact 
cells. HEK-293 cells stably expressing human 11-HSD1 and 
H6PDH were treated with 1 M of 7k27OHC with or without the 
11-HSD1 inhibitor T0504 (A) or 1 M of 727OHC or 727OHC 
(B) for 60 min. 7k27OHC, 727OHC, and 727OHC concentra-
tions were determined using UHPLC-MS/MS. Data represent the 
mean ± SD from three independent experiments.
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total protein1 for cortisone (46) as substrate (Table 1). No 
727OHC was generated. Moreover, neither 727OHC 
nor 727OHC was oxidized by 11-HSD1 under the condi-
tions applied and no isomerase activity could be detected 
(Fig. 1B). Enzyme kinetic analysis using microsomal 
preparations revealed an estimated apparent KMapp value 
of 39 ± 12 nM and an apparent Vmax app value of 4.3 ± 0.2 
nmol·h1·mg total protein1 for the oxoreduction of 
7k27OHC to 727OHC by 11-HSD1 (Table 1). Addition-
ally, mouse 11-hsd1 also showed the exclusive conversion 
of 7k27OHC to 727OHC without the formation 727OHC 
(data not shown).
11-HSD2-dependent oxidation of 727OHC
The role of 11-HSD2 in the metabolism of 7-oxygen-
ated 27OHCs was then assessed in HEK-293 cells stably ex-
pressing the recombinant human enzyme. Treatment for 
30 min with 500 nM of 727OHC or 727OHC showed the 
exclusive oxidation of 727OHC to 7k27OHC (Fig. 2A) 
and a lack of 727OHC metabolism (Fig. 2B, supplemental 
Fig. S2). Apparent enzyme velocity values were determined 
as 0.6 ± 0.1 nmol·h1·mg total protein1 for 727OHC and 
1.01 ± 0.35 nmol·h1·mg total protein1 for cortisol (46) 
(Table 1). Furthermore, neither an oxoreductase nor an 
isomerase activity of 11-HSD2 could be detected (Fig. 
2B). Kinetic analyses of the oxidation reaction of 727OHC 
to 7k27OHC revealed a KMapp value of 56 ± 11 nM and a 
Vmax app of 10 ± 0.4 nmol·h
1·mg total protein1, following 
a Michaelis-Menten-type response (Table 1).
Metabolism of 7OHC by CYP27A1 and 11-HSD2
It was recently suggested that 727OHC formation in-
cludes in a first step an oxidation from 7OHC to 7kC by 
11-HSD2, followed by hydroxylation at position 27 by 
CYP27A1 to 7k27OHC and then reduction of 7k27OHC to 
727OHC by reactive oxygen species (29). Because reduc-
tive reactions by reactive oxygen species are highly un-
likely, we tested the hypothesis of 27-hydroxylation of 
7OHC and subsequent oxidation to 7k27OHC in SW-620 
colon cancer cells endogenously expressing CYP27A1 and 
11-HSD2. SW-620 cells were treated with 1 M of 7OHC 
in the presence or absence of the 11-HSD2 inhibitor, GA, 
and the formation of 727OHC (Fig. 3A) and 7k27OHC 
(Fig. 3B) was evaluated. 727OHC was generated in a 
time-dependent manner from 7OHC by CYP27A1 and 
then further oxidized by 11-HSD2 to 7k27OHC.
Oxysterol-dependent inhibition of 11-HSD enzyme 
activities
To assess the potential of 7-oxygenated 27OHCs to inter-
fere with the metabolism of glucocorticoids, oxysterol-
dependent inhibition of 11-HSD enzyme activities were 
measured in lysates of HEK-293 cells expressing the re-
spective enzymes. 7k27OHC inhibited the 11-HSD1-
dependent conversion of cortisone to cortisol with an IC50 
value of 357 ± 38 nM for the human enzyme (Fig. 4A) and 
of 36 ± 2 nM for the mouse ortholog (Fig. 4B). Only weak 
inhibition of human 11-HSD1 (IC50 value 3 M) was 
detected for 727OHC, whereas 727OHC did not inhibit 
the enzyme activity at concentrations up to 10 M (data 
not shown). However, mouse 11-hsd1 enzyme activity was 
potently inhibited by 727OHC with an IC50 value of 66 ± 
11 nM (Fig. 4C) and 1 M 727OHC revealed 30% rest 
enzyme activity (data not shown).
11-HSD2-dependent conversion of cortisol to corti-
sone was effectively inhibited by 727OHC and 7k27OHC 
with IC50 values of 11 ± 2 nM and 15 ± 1 nM, respectively 
(Fig. 5); however, 727OHC did not inhibit (not shown). 
Mouse kidney homogenates, expressing high levels of 
11-hsd2, were used to determine the interference of 
oxysterols with the metabolism of corticosterone to 
11-dehydrocorticosterone (11-DHC). Neither 727OHC 
nor 727OHC inhibited the 11-hsd2 activity, whereas 
7k27OHC was a weak inhibitor with an IC50 value of 1.65 ± 
0.4 M (supplemental Fig. S3). Because diminished 
11-HSD2 activity has been associated with proinflamma-
tory effects and an accelerated formation of atheroscle-
rotic lesions in Apoe/11-hsd2/ double-knockout 
mice, due to cortisol-dependent activation of the MR (47), 
11-HSD2-MR-dependent reporter gene assays were 
performed. For this purpose, HEK-293 cells stably ex-
pressing 11-HSD2 were transfected with plasmids for 
MR and a MR-dependent luciferase reporter gene prior 
to treatment with cortisol and 7-oxygenated 27OHCs. 
Following inhibition of 11-HSD2 by 727OHC and 
7k27OHC, less cortisol was inactivated to cortisone and 
thereby an increased (3.5 times) cortisol-dependent 
MR activation (with EC50 values of 354 ± 55 nM for 
727OHC and 331 ± 121 nM for 7k27OHC) compared 
with the exclusive activation by 50 nM cortisol could be 
detected (supplemental Fig. S4). Importantly, neither 
727OHC nor 7k27OHC was able to stimulate MR activity 
by itself (data not shown).
TABLE 1. Kinetic parameters
Enzyme Reaction KMapp (nM)
Vmax app (nmol·h
1·mg total 
protein1)
Vapp cell intact (nmol·h
1·mg 
total protein1)
11-HSD1 7k27OHC → 727OHC 39 ± 12 4.3 ± 0.2 0.52 ± 0.10a
Cortisone → cortisol 250–500 (19, 34) — 1.59 ± 0.25 (46)
11-HSD2 727OHC → 7k27OHC 56 ± 11 10 ± 0.4 0.6 ± 0.1b
Cortisol → cortisone 200 (34) — 1.01 ± 0.35 (46)
Comparison of the oxoreduction of 7k27OHC and cortisone by 11-HSD1 and the oxidation of 727OHC and 
cortisol by 11-HSD2. Data represent mean ± SD from three independent experiments.
a A substrate concentration of 1 M was used for the reaction.
b A substrate concentration of 500 nM was used.
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11-HSD docking calculations
Molecular docking calculations were implemented to 
predict the binding orientations of 7k27OHC, 727OHC 
and 727OHC in the substrate binding pockets of 11-
HSDs and, thus, providing a potential explanation for the 
results obtained from the enzyme activity measurements. 
7k27OHC, cortisone, and 11-DHC were found to fit within 
comparable distances to the nicotinamide ring of the co-
factor (NADPH) as well as to the catalytic residues Tyr183 
and Ser170 of human and mouse 11-HSD1 (Fig. 6A, C). 
Moreover, the enzymatic product, 727OHC, was orien-
tated toward the important residues of the catalytic triad 
and the cofactor within similar distances as the substrates 
to 11-HSD1 of both species (Fig. 6B, D). Compared 
with 727OHC, 727OHC adopted a slightly turned up-
wards binding orientation in the binding cavity of human 
11-HSD1 and, therefore, showed increased distances 
to Tyr183, Ser170, and particularly to NAPDH (Fig. 6B). 
However, docking analysis of 727OHC to mouse 11-hsd1 
displayed a more favorable alignment with similar distances 
as the substrates to the binding pocket (Fig. 6D).
Homology models were used for docking analyses due 
to the absence of 11-HSD2 crystal structures. 727OHC 
and 7k27OHC were found in close distance to the cofac-
tor NAD+ (1.0–1.2 Å) and the catalytic residue Tyr232 
(2.8–3.4 Å), whereas 727OHC fitted again in a turned 
upwards position with enlarged distances into the sub-
strate binding site of human 11-HSD2 (Fig. 7A). A con-
siderable species-specific difference was found between 
the murine and the human 11-HSD2 substrate-binding 
cavity: in close distance to the catalytic residues and the 
cofactor-binding site, the residue Trp276 limited the size 
of the substrate-binding pocket and constricted the murine 
enzyme. In the human model, however, this residue was 
located outside of the binding cavity. Hence, steric clashes 
with Trp276 were observed when docking 727OHC, 
727OHC, and 7k27OHC to mouse 11-hsd2, providing a 
possible explanation for their weak or inactive interaction 
potential (Fig. 7B).
Prereceptor regulation of ROR by 11-HSDs
A recent study identified 727OHC as an endogenously 
occurring ROR agonist, whereas 7k27OHC was not able 
to stimulate full-length ROR activity in reporter gene 
assays (31). Thus, the capacity of 11-HSDs to act as 
metabolic regulators, providing or inactivating the ROR 
ligand, was examined. To obtain these insights, CHO cells 
stably expressing a Tet-on ROR vector and a RORE-Luc 
reporter were additionally transfected with either an 
hH6PDH-IRES-hHSD11B1 construct (Fig. 8A) or 11-HSD2 
(Fig. 8B) and subjected to treatment with 7k27OHC and 
727OHC. 7k27OHC was capable of reversing the inhibi-
tory effect of the ROR antagonist, SR2211, in the same 
manner as 727OHC (white dots, continuous line) upon 
coexpression of ROR with 11-HSD1 (black dots, con-
tinuous line) compared with the control (black dots, 
dashed line). Treating 11-HSD2 expressing ROR Tet-
on cells with 727OHC could not restore ROR activity 
and showed the same weak response as 7k27OHC. Addi-
tionally, treating the cells with 727OHC exhibited the 
same weak concentration-dependent effect as 7k27OHC 
when expressing only the control plasmid (data not 
shown).
Fig. 2. 11-HSD2-dependent metabolism of 727OHC in intact 
cells. HEK-293 cells stably expressing human 11-HSD2 were 
treated with 500 nM of 727OHC with or without 5 M of the 11-
HSD inhibitor GA (A) or 500 nM of 7k27OHC or 727OHC (B) for 
30 min. 7k27OHC, 727OHC, and 727OHC concentrations were 
determined using UHPLC-MS/MS. Data represent the mean ± SD 
from three independent experiments.
Fig. 3. Metabolism of 7OHC in SW-620 cells 
endogenously expressing CYP27A1 and 11-HSD2. 
SW-620 cells were treated with 1 M of 7OHC in 
the presence or absence of 10 M of GA for 3.5 h 
(white bars) or 7 h (gray bars). Qualitative analysis of 
727OHC (A) and 7k27OHC (B) using the respective 
areas under the curve (AUC) normalized to the ISTD 
are illustrated. Data represent the mean ± SD from 
three independent experiments.
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DISCUSSION
The family of oxysterols comprises a large number of 
compounds; however, their abundance in biological sys-
tems is low compared with cholesterol (1). Because several 
enzymes may act on a given metabolite and the enzymes 
involved often exhibit promiscuous substrate specificities, 
the analysis of their biosynthetic pathways is challenging. 
Moreover, oxysterols possess a high susceptibility for autoxi-
dation, predisposing them to biased study results (1). For 
example, 727OHC can be formed either by oxoreduction 
of 7kC through 11-HSD1 to 7OHC and then further by 
hydroxylation to 727OHC through CYP27A1 or via direct 
hydroxylation of autoxidation-derived 7OHC by CYP27A1. 
We showed two novel alternative biosynthetic pathways, i.e., 
the 11-HSD1-dependent generation of 727OHC and the 
11-HSD2-dependent formation of 7k27OHC. Besides 
the 11-HSD-dependent interconversion of the mono-
hydroxylated oxysterols, 7kC and 7OHC (19–21, 29), the 
only reported enzymatic reaction catalyzed by 11-HSD2 
involving oxysterols was, until now, the oxidation of 
cholestane-3,5,6-triol to the oncometabolite, 6-oxo-
cholestane-3,5-diol, and the reverse reduction reaction 
through 11-HSD1 (48). Cholestane-3,5,6-triol is formed 
from autoxidation-derived cholesterol-5,6-epoxide upon 
metabolism by cholesterol-epoxide hydrolase. The current 
study shows for the first time an involvement of 11-HSDs 
in the interconversion of side chain-oxidized oxysterols, 
with relevance for ROR activation (Fig. 9).
Kinetic analysis revealed remarkably high substrate af-
finities with estimated KMapp values in the lower nanomolar 
range of 11-HSD1 and 11-HSD2 for 7k27OHC and 
727OHC, respectively. The affinity of 11-HSD1 for 
7k27OHC obtained in the present study is 6-25 times 
higher than the affinities previously reported for other en-
dogenously occurring substrates (cortisone and 11-DHC, 
KMapp 250-500 nM (19, 34); 7kC, KMapp 500 nM (19); 
and 7oxoLCA, KMapp 1000 nM (49)). Moreover, the sub-
strate affinity of 11-HSD2 for 727OHC is 4 times 
higher than that of the previously reported cortisol (KMapp 
200 nM) (34).
Apart from their own metabolic conversion by 11-
HSDs, 7k27OHC and 727OHC may alter other 11-HSD-
dependent reactions by competing with these substrates at 
the substrate-binding pocket and thereby inhibiting the 
corresponding reaction. In this regard, 7k27OHC moder-
ately inhibited the oxoreduction of cortisone to cortisol by 
human 11-HSD1 (IC50 value of 357 nM), therefore less 
likely being of physiological relevance. In contrast, the in-
hibitory capacities of 7k27OHC and 727OHC (IC50 values 
of 15 nM and 11 nM, respectively) to interfere with (hu-
man) 11-HSD2-dependent oxidation of cortisol belong to 
the most potent endogenous 11-HSD2 inhibitors discov-
ered so far (50). Upon inhibition of 11-HSD2, less cortisol 
is inactivated, resulting in higher cortisol availability and 
activation of the MR, as shown in transactivation assays. A 
role for endogenously formed compounds inhibiting 11-
HSD2 function was raised by the GA-like factor (GALF) 
Fig. 4. Inhibition of human (A) and murine (B, C) 
11-HSD1-dependent oxoreduction of cortisone by 
7k27OHC and 727OHC. HEK-293 cell lysates ex-
pressing recombinant human 11-HSD1 and H6PDH 
or murine 11-hsd1 were incubated with 200 nM of 
radiolabeled cortisone, 500 M of NADPH, and in-
creasing concentrations of 7k27OHC (A, B) and 
727OHC (C) for 10 min at 37°C. Cortisone to corti-
sol conversion was determined and compared with the 
enzyme activity in the control samples (0.1% DMSO). 
Data represent the mean ± SD from three indepen-
dent experiments.
Fig. 5. Inhibition of human 11-HSD2-dependent 
oxidation of cortisol by 727OHC and 7k27OHC. 
Lysates of HEK-293 cells expressing recombinant human 
11-HSD2 were incubated with 50 nM of radiolabeled 
cortisol, 500 M of NAD+, and increasing concentra-
tions of 727OHC (A) and 7k27OHC (B) for 10 min at 
37°C. Cortisol to cortisone conversion was determined 
and compared with the enzyme activity in the control 
samples (0.1% DMSO). Data represent the mean ± SD 
from three independent experiments.
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hypothesis implicating an involvement in the etiology of 
not only essential hypertension but also colorectal cancer 
(50). Such GALFs, derived from peripheral tissues, the 
adrenal glands, or the gut microbiome could allow cortisol 
to act as a mineralocorticoid, leading to increased Na+ 
retention and hypertension (50, 51). Furthermore, they 
may cause elevated intracellular levels of active glucocorti-
coids, suppressing colorectal tumorigenesis and metastasis 
through different mechanisms.
An important question addresses the physiological 
relevance of plasma levels measured for potential GALF 
substances or oxysterols. Due to the lipophilic nature of 
oxysterols and the localized expression of oxysterol metab-
olizing enzymes, their formation and, thus, locally increased 
concentrations may not be represented by plasma concen-
trations. Hence, to understand oxysterol-related mecha-
nisms, it is necessary to assess the tissue-specific or even 
cell-specific localization of biotransformation pathways and 
the involved substrate and product concentrations. The 
presented experiments using SW-620 colon carcinoma 
cells revealed a time-dependent formation of 7k27OHC by 
CYP27A1 and 11-HSD2 from 7OHC, with an accumula-
tion of 727OHC upon inhibition of 11-HSD2. Substan-
tial concentrations of 7kC and 7OHC may be reached 
in the gastrointestinal tract and in the liver following the 
intake of processed cholesterol-rich food. Both 7kC and 
7OHC were reported to induce inappropriate responses 
to the intestinal epithelium and thereby may disrupt the 
intestinal barrier integrity [reviewed in (52, 53)]. Whether 
these effects are due to 7-oxygenated 27OHC remains to be 
elucidated. Interestingly, innate lymphoid group 3 (ILC3) 
cells, which are expressed by the intestinal lymphoid tissue 
and characterized by the expression of the transcription 
factor, RORt, have been described to contribute to the 
regulation of the intestinal barrier (53, 54). However, a 
hyperactivation of these RORt-positive ILC3 cells has 
been described to contribute to intestinal inflammation 
(54). Because the nuclear receptors ROR and RORt are 
activated by 727OHC, but not or only weakly by 7k27OHC 
when full-length receptors are considered [(31), present 
study], 11-HSDs may have an important role by either 
providing the active ligand 727OHC (cells expressing 
11-HSD1) or protecting the receptors from activation 
(cells expressing 11-HSD2). Considering that an overstim-
ulation of ILC3 cells could disturb the intestinal barrier 
function, a protective role for 11-HSD2 by inactivating the 
ROR ligand 727OHC to 7k27OHC is suggested, whereas 
11-HSD1 might aggravate the disturbance. Furthermore, 
recent evidence proposed that the intestinal lymphoid tis-
sue plays a role in the pathology of inflammatory bowel 
Fig. 6. Predicted binding of cortisone, 11-DHC, 7k27OHC, 727OHC, and 727OHC to the binding pocket of human (A, B) and murine 
(C, D) 11-HSD1. A: Representative binding poses of cortisone (blue), 7k27OHC (green), and 727OHC (purple). Important interactions 
for protein-ligand binding and the cofactor are shown in stick style and corresponding distances in ångstroms are indicated as dashed lines 
(same color code as docked ligands). B: Binding mode of 727OHC and 727OHC (salmon pink). C: Representative binding poses of 11-
DHC (turquoise) and 7k27OHC. Important interactions for protein-ligand binding and the cofactor are shown in stick style and correspond-
ing distances in ångstroms are indicated as dashed lines (same color code as docked ligands). D: Binding mode of 7k27OHC, 727OHC, and 
727OHC.
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disease (IBD) (55). A subgroup of ILC3s was shown to 
aggregate in ulcerative colitis and correlate with disease 
severity [reviewed in (53)]. Moreover, a dysregulation of 
colonic 11-HSD expression has been associated with IBD 
progression and with increased 11-HSD1 and decreased 
11-HSD2 expression (56–59). This would shift the bal-
ance form the inactive ROR(t) ligand, 7k27OHC, to the 
agonist, 727OHC. However, whether this prereceptor 
regulation of ROR and RORt by 11-HSDs is involved in 
the pathology of IBD requires further careful and thorough 
experimental investigation.
It needs to be noted that the mouse is of limited use 
to address the 11-HSD-dependent regulation of ROR(t). 
Our data indicate that while human and murine 11-HSD1 
both accept 7k27OHC as substrate and 7k27OHC effec-
tively competes with cortisone at the substrate biding 
pocket, 727OHC is a high-affinity substrate for human 
11-HSD2 but seems to be unable to efficiently compete 
with cortisol for binding to the murine enzyme due to steric 
hindrance.
Nevertheless, the regulation of ROR(t) by 11-HSDs 
should be further investigated in relevant human cell mod-
els with endogenous expression of these proteins. How-
ever, in vitro assessment of the function of endogenously 
expressed ROR using cell lines is highly complex and suit-
able cell models have not yet been identified. It is still 
unclear whether RORs are constitutively active receptors 
or whether their activities are driven by endogenously 
occurring (not yet characterized) ligands, including differ-
ent oxysterols or intermediates of the cholesterol biosyn-
thetic pathway. Compounds of the culture medium and of 
the cholesterol biosynthetic pathway in a cell endogenously 
expressing ROR might control receptor activity and affect 
target gene expression. Furthermore, ROR can be coex-
pressed with ROR and/or the transcriptional repressor, 
Rev-Erb, that both can bind to the same RORE response 
element on promoter regions of target genes (60). The 
assessment of ROR target gene expression can be strongly 
influenced by ROR and occasionally also by other nuclear 
receptors and receptor-associated coregulators that are tis-
sue- and cell-specifically expressed. Therefore, the identifi-
cation of a suitable cell model endogenously co-expressing 
ROR with correspondingly responsive target genes and 
either 11-HSD1 or 11-HSD2 remains challenging. Alter-
natively, cells might be transfected with a ROR-responsive 
reporter gene to achieve a more reliable readout.
To the best of our knowledge, very few human cell lines 
endogenously express substantial levels of 11-HSD1, 
usually only following differentiation. A series of our own 
previous experiments with human and murine macro-
phages, myocytes, and adipocytes have shown that their 
Fig. 7. Predicted binding of 7k27OHC, 727OHC, and 727OHC 
to human (A) and murine (B) 11-HSD2. Representative binding 
poses of 7k27OHC (orange), 727OHC (turquoise), and 727OHC 
(gray). Important interactions for protein-ligand binding and the 
cofactor are shown in stick style and corresponding distances in 
ångstroms are indicated as dashed lines (same color code as docked 
ligands).
Fig. 8. ROR-mediated activation of the luciferase 
reporter by 7,27OHCs in CHO Tet-on cells transfected 
with either 11-HSD1 (A) or 11-HSD2 (B). Reversal 
of the inhibitory effect of the inverse agonist SR2211 
by the addition of 7k27OHC or 727OHC and its 
dependence on 11-HSD1 or 11-HSD2. The reporter 
activation was illustrated as fold change over the 
inverse agonist SR2211. Data represent the mean ± SD 
from at least three independent experiments.
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differentiation is severely disturbed after transfection and 
that 11-HSD1 expression is abolished, making these cell 
lines inapplicable to efficiently study ROR regulation.
With respect to 11-HSD2, we had used, in a series of 
preliminary experiments, SW-620 cells that express endog-
enous ROR and also ROR and observed activation of a 
previously reported glucose-6-phosphatase luciferase con-
struct (33). The potent ROR inverse agonist, GSK2981278, 
was able to inhibit the reporter gene, although at high con-
centrations (IC50 of 10 M); in contrast, the less potent in-
verse agonist, SR2211, failed to do so. Because endogenous 
expression of ROR and/or Rev-Erb may interfere with 
ROR activity, we then overexpressed ROR in SW-620 
cells, which resulted in a more pronounced response and a 
concentration-dependent decrease of the reporter gene 
activity by both GSK2981278 and SR2211 (with an IC50 of 
approximately 0.5 M for the latter). Our preliminary data 
showed that inhibition of 11-HSD2 in these cells by GA 
resulted in a trend toward enhanced ROR activity (ap-
proximately 10% increase) compared with cells treated 
with 727OHC only. This suggests that the conversion of 
727OHC to 7k27OHC by 11-HSD2 partially protected 
ROR from 727OHC but that the experimental setting 
was not suitable to detect 11-HSD2-dependent protection 
of 727OHC-mediated ROR activation. In addition, 
knockdown of 11-HSD2 by siRNA instead of pharmaco-
logical inhibition did not result in a more pronounced ef-
fect. The following reasons might explain the failure to 
detect 11-HSD2-dependent regulation of ROR in our 
experimental setting: a) autoxidation (thereby inactivation 
of 727OHC and insufficient competition with the ROR 
inverse agonist); b) further metabolism of the oxysterols 
during the experiment; c) generation of other ROR ago-
nists by the cell (for example, formation of 27OHC from 
cholesterol by CYP27A1); d) inappropriate timing (result-
ing in reporter gene activation before 727OHC is inacti-
vated by 11-HSD2); and e) insufficient competition with 
the inverse agonist (not reaching intracellular concentra-
tions successfully competing with the inverse agonist). 
Thus, the SW-620 cell line has proven useful to study the 
enzymatic conversion of 7OHC to 7k27OHC; however, it 
seems unsuitable to study the 11-HSD2-mediated prere-
ceptor regulation of ROR.
Future efforts should focus on the identification of suit-
able cell models, including co-culture models to address 
possible paracrine effects, to investigate the control of 
ROR activity by 11-HSDs. Moreover, the role of 11-
HSDs on tissue-specific control of 727OHC levels should 
be studied in vivo in situations where the activities of these 
enzymes are impaired.
In conclusion, the present study demonstrated the 
stereospecific oxoreduction of 7k27OHC to 727OHC by 
11-HSD1 and the reverse oxidation reaction from 727OHC 
to 7k27OHC catalyzed by human 11-HSD2 (Fig. 9). 
The apparent affinities of 11-HSD1 and 11-HSD2 for the 
7-oxygenated oxysterols were equal or higher than for the 
glucocorticoids, indicating that they are preferred substrates. 
Furthermore, by supplying either 727OHC, the active 
ligand of ROR, or inactivating 727OHC to 7k27OHC, a 
novel glucocorticoid-independent prereceptor regulation 
mechanism by 11-HSDs could be shown. Future research 
to identify suitable cell models to characterize the control 
of ROR activity by 11-HSDs and to assess the relevance of 
11-HSDs in the metabolism of 7-oxygenated oxysterols is 
warranted.
The authors thank Dr. Thierry Langer, University of Vienna and 
Inte:Ligand GmbH, for providing the LigandScout software, Dr. 
Daniela Schuster, Paracelsus Medical University Salzburg, for 
providing GOLD software, and Dr. Klaus Seuwen, Novartis 
Institute for BioMedical Research Basel, for expert input to the 
project.
REFERENCES
 1. Schroepfer, G. J., Jr. 2000. Oxysterols: modulators of cholesterol 
metabolism and other processes. Physiol. Rev. 80: 361–554.
 2. Guillemot-Legris, O., V. Mutemberezi, and G. G. Muccioli. 2016. 
Oxysterols in metabolic syndrome: from bystander molecules to bio-
active lipids. Trends Mol. Med. 22: 594–614.
 3. Zarrouk, A., A. Vejux, J. Mackrill, Y. O’Callaghan, M. Hammami, 
N. O’Brien, and G. Lizard. 2014. Involvement of oxysterols in age-
related diseases and ageing processes. Ageing Res. Rev. 18: 148–162.
 4. Jeitner, T. M., I. Voloshyna, and A. B. Reiss. 2011. Oxysterol de-
rivatives of cholesterol in neurodegenerative disorders. Curr. Med. 
Chem. 18: 1515–1525.
 5. Poli, G., F. Biasi, and G. Leonarduzzi. 2013. Oxysterols in the patho-
genesis of major chronic diseases. Redox Biol. 1: 125–130.
 6. Silvente-Poirot, S., F. Dalenc, and M. Poirot. 2018. The effects of 
cholesterol-derived oncometabolites on nuclear receptor function 
in cancer. Cancer Res. 78: 4803–4808.
 7. Vejux, A., and G. Lizard. 2009. Cytotoxic effects of oxysterols associ-
ated with human diseases: Induction of cell death (apoptosis and/
or oncosis), oxidative and inflammatory activities, and phospholipi-
dosis. Mol. Aspects Med. 30: 153–170.
 8. Brown, A. J., and W. Jessup. 1999. Oxysterols and atherosclerosis. 
Atherosclerosis. 142: 1–28.
 9. Song, J., D. Wang, H. Chen, X. Huang, Y. Zhong, N. Jiang, C. Chen, 
and M. Xia. 2017. Association of plasma 7-ketocholesterol with car-
diovascular outcomes and total mortality in patients with coronary 
artery disease. Circ. Res. 120: 1622–1631.
 10. Girão, H., M. C. Mota, J. Ramalho, and P. Pereira. 1998. Cholesterol 
oxides accumulate in human cataracts. Exp. Eye Res. 66: 645–652.
 11. Björkhem, I., O. Andersson, U. Diczfalusy, B. Sevastik, R. J. Xiu, C. 
Duan, and E. Lund. 1994. Atherosclerosis and sterol 27-hydroxylase: 
Fig. 9. Control of ROR ligand 727OHC availability by 11-HSDs.
 by guest, on Septem
ber 25, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2019/07/04/jlr.M092908.DC1
Supplemental Material can be found at:
11-HSDs control 7,27-dihydroxycholesterol access to ROR 1545
evidence for a role of this enzyme in elimination of cholesterol from 
human macrophages. Proc. Natl. Acad. Sci. USA. 91: 8592–8596.
 12. Brown, A. J., S. L. Leong, R. T. Dean, and W. Jessup. 1997. 
7-Hydroperoxycholesterol and its products in oxidized low den-
sity lipoprotein and human atherosclerotic plaque. J. Lipid Res. 38: 
1730–1745.
 13. Brown, A. J., G. F. Watts, J. R. Burnett, R. T. Dean, and W. Jessup. 
2000. Sterol 27-hydroxylase acts on 7-ketocholesterol in human ath-
erosclerotic lesions and macrophages in culture. J. Biol. Chem. 275: 
27627–27633.
 14. Heo, G. Y., I. Bederman, N. Mast, W. L. Liao, I. V. Turko, and I. 
A. Pikuleva. 2011. Conversion of 7-ketocholesterol to oxysterol me-
tabolites by recombinant CYP27A1 and retinal pigment epithelial 
cells. J. Lipid Res. 52: 1117–1127.
 15. Fujiyama, J., M. Kuriyama, S. Arima, Y. Shibata, K. Nagata, S. 
Takenaga, H. Tanaka, and M. Osame. 1991. Atherogenic risk fac-
tors in cerebrotendinous xanthomatosis. Clin. Chim. Acta. 200: 1–11.
 16. Javitt, N. B. 1994. Bile acid synthesis from cholesterol: regulatory 
and auxiliary pathways. FASEB J. 8: 1308–1311.
 17. Lyons, M. A., and A. J. Brown. 2001. Metabolism of an oxysterol, 
7-ketocholesterol, by sterol 27-hydroxylase in HepG2 cells. Lipids. 
36: 701–711.
 18. Lyons, M. A., N. Maeda, and A. J. Brown. 2002. Paradoxical en-
hancement of hepatic metabolism of 7-ketocholesterol in ste-
rol 27-hydroxylase-deficient mice. Biochim. Biophys. Acta. 1581: 
119–126.
 19. Schweizer, R. A., M. Zurcher, Z. Balazs, B. Dick, and A. Odermatt. 
2004. Rapid hepatic metabolism of 7-ketocholesterol by 11beta-
hydroxysteroid dehydrogenase type 1: species-specific differences 
between the rat, human, and hamster enzyme. J. Biol. Chem. 279: 
18415–18424.
 20. Hult, M., B. Elleby, N. Shafqat, S. Svensson, A. Rane, H. Jornvall, 
L. Abrahmsen, and U. Oppermann. 2004. Human and rodent type 
1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholes-
terol dehydrogenases involved in oxysterol metabolism. Cell. Mol. 
Life Sci. 61: 992–999.
 21. Arampatzis, S., B. Kadereit, D. Schuster, Z. Balazs, R. A. Schweizer, 
F. J. Frey, T. Langer, and A. Odermatt. 2005. Comparative enzymol-
ogy of 11beta-hydroxysteroid dehydrogenase type 1 from six spe-
cies. J. Mol. Endocrinol. 35: 89–101.
 22. Mitić, T., S. Shave, N. Semjonous, I. McNae, D. F. Cobice, G. G. 
Lavery, S. P. Webster, P. W. Hadoke, B. R. Walker, and R. Andrew. 
2013. 11beta-Hydroxysteroid dehydrogenase type 1 contributes 
to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo. 
Biochem. Pharmacol. 86: 146–153.
 23. Odermatt, A., and P. Klusonova. 2015. 11beta-Hydroxysteroid dehy-
drogenase 1: Regeneration of active glucocorticoids is only part of 
the story. J. Steroid Biochem. Mol. Biol. 151: 85–92.
 24. Mitić, T., R. Andrew, B. R. Walker, and P. W. Hadoke. 2013. 11beta-
Hydroxysteroid dehydrogenase type 1 contributes to the regulation 
of 7-oxysterol levels in the arterial wall through the inter-conversion 
of 7-ketocholesterol and 7beta-hydroxycholesterol. Biochimie. 95: 
548–555.
 25. Hermanowski-Vosatka, A., J. M. Balkovec, K. Cheng, H. Y. Chen, M. 
Hernandez, G. C. Koo, C. B. Le Grand, Z. Li, J. M. Metzger, S. S. 
Mundt, et al. 2005. 11beta-HSD1 inhibition ameliorates metabolic 
syndrome and prevents progression of atherosclerosis in mice. J. 
Exp. Med. 202: 517–527.
 26. Luo, M. J., R. Thieringer, M. S. Springer, S. D. Wright, A. 
Hermanowski-Vosatka, A. Plump, J. M. Balkovec, K. Cheng, G. J. 
Ding, D. W. Kawka, et al. 2013. 11beta-HSD1 inhibition reduces ath-
erosclerosis in mice by altering proinflammatory gene expression in 
the vasculature. Physiol. Genomics. 45: 47–57.
 27. Kipari, T., P. W. Hadoke, J. Iqbal, T. Y. Man, E. Miller, A. E. 
Coutinho, Z. Zhang, K. M. Sullivan, T. Mitic, D. E. Livingstone, 
et al. 2013. 11beta-hydroxysteroid dehydrogenase type 1 deficiency 
in bone marrow-derived cells reduces atherosclerosis. FASEB J. 27: 
1519–1531.
 28. Savouret, J. F., M. Antenos, M. Quesne, J. Xu, E. Milgrom, and R. F. 
Casper. 2001. 7-ketocholesterol is an endogenous modulator for the 
arylhydrocarbon receptor. J. Biol. Chem. 276: 3054–3059.
 29. Raleigh, D. R., N. Sever, P. K. Choksi, M. A. Sigg, K. M. Hines, B. 
M. Thompson, D. Elnatan, P. Jaishankar, P. Bisignano, F. R. Garcia-
Gonzalo, et al. 2018. Cilia-associated oxysterols activate smooth-
ened. Mol. Cell. 26: 346–357. e315.
 30. Myers, B. R., N. Sever, Y. C. Chong, J. Kim, J. D. Belani, S. Rychnovsky, 
J. F. Bazan, and P. A. Beachy. 2013. Hedgehog pathway modulation 
by multiple lipid binding sites on the smoothened effector of signal 
response. Dev. Cell. 26: 346–357.
 31. Soroosh, P., J. Wu, X. Xue, J. Song, S. W. Sutton, M. Sablad, J. Yu, M. 
I. Nelen, X. Liu, G. Castro, et al. 2014. Oxysterols are agonist ligands 
of RORgammat and drive Th17 cell differentiation. Proc. Natl. Acad. 
Sci. USA. 111: 12163–12168.
 32. Smith, S. H., C. E. Peredo, Y. Takeda, T. Bui, J. Neil, D. Rickard, 
E. Millerman, J. P. Therrien, E. Nicodeme, J. M. Brusq, et al. 
2016. Development of a topical treatment for psoriasis targeting 
RORgamma: from bench to skin. PLoS One. 11: e0147979.
 33. Slominski, A. T., T. K. Kim, Y. Takeda, Z. Janjetovic, A. A. Brozyna, 
C. Skobowiat, J. Wang, A. Postlethwaite, W. Li, R. C. Tuckey, et al. 
2014. RORalpha and ROR gamma are expressed in human skin and 
serve as receptors for endogenously produced noncalcemic 20-hy-
droxy- and 20,23-dihydroxyvitamin D. FASEB J. 28: 2775–2789.
 34. Schweizer, R. A., A. G. Atanasov, B. M. Frey, and A. Odermatt. 2003. 
A rapid screening assay for inhibitors of 11beta-hydroxysteroid de-
hydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-
HSD1 reductase activity. Mol. Cell. Endocrinol. 212: 41–49.
 35. Gumy, C., C. Thurnbichler, E. M. Aubry, Z. Balazs, P. Pfisterer, L. 
Baumgartner, H. Stuppner, A. Odermatt, and J. M. Rollinger. 2009. 
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 by plant 
extracts used as traditional antidiabetic medicines. Fitoterapia. 80: 
200–205.
 36. Atanasov, A. G., L. G. Nashev, R. A. Schweizer, C. Frick, and A. 
Odermatt. 2004. Hexose-6-phosphate dehydrogenase determines 
the reaction direction of 11beta-hydroxysteroid dehydrogenase type 
1 as an oxoreductase. FEBS Lett. 571: 129–133.
 37. Liu, W., L. Xu, C. R. Lamberson, L. S. Merkens, R. D. Steiner, E. R. 
Elias, D. Haas, and N. A. Porter. 2013. Assays of plasma dehydro-
cholesteryl esters and oxysterols from Smith-Lemli-Opitz syndrome 
patients. J. Lipid Res. 54: 244–253.
 38. Dzyakanchuk, A. A., Z. Balazs, L. G. Nashev, K. E. Amrein, and A. 
Odermatt. 2009. 11beta-Hydroxysteroid dehydrogenase 1 reduc-
tase activity is dependent on a high ratio of NADPH/NADP(+) 
and is stimulated by extracellular glucose. Mol. Cell. Endocrinol. 301: 
137–141.
 39. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. 
Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. 
Olson, and D. C. Klenk. 1985. Measurement of protein using bicin-
choninic acid. Anal. Biochem. 150: 76–85.
 40. Kratschmar, D. V., A. Vuorinen, T. Da Cunha, G. Wolber, D. 
Classen-Houben, O. Doblhoff, D. Schuster, and A. Odermatt. 2011. 
Characterization of activity and binding mode of glycyrrhetinic acid 
derivatives inhibiting 11beta-hydroxysteroid dehydrogenase type 2. 
J. Steroid Biochem. Mol. Biol. 125: 129–142.
 41. Beck, K. R., M. Bachler, A. Vuorinen, S. Wagner, M. Akram, U. 
Griesser, V. Temml, P. Klusonova, H. Yamaguchi, D. Schuster, et al. 
2017. Inhibition of 11beta-hydroxysteroid dehydrogenase 2 by the 
fungicides itraconazole and posaconazole. Biochem. Pharmacol. 130: 
93–103.
 42. Jones, G., P. Willett, R. C. Glen, A. R. Leach, and R. Taylor. 1997. 
Development and validation of a genetic algorithm for flexible 
docking. J. Mol. Biol. 267: 727–748.
 43. Wolber, G., and T. Langer. 2005. LigandScout: 3-D pharmacoph-
ores derived from protein-bound ligands and their use as virtual 
screening filters. J. Chem. Inf. Model. 45: 160–169.
 44. Yamaguchi, H., T. Akitaya, T. Yu, Y. Kidachi, K. Kamiie, T. Noshita, 
H. Umetsu, and K. Ryoyama. 2011. Homology modeling and struc-
tural analysis of 11beta-hydroxysteroid dehydrogenase type 2. Eur. J. 
Med. Chem. 46: 1325–1330.
 45. Yamaguchi, H., T. Akitaya, Y. Kidachi, K. Kamiie, T. Noshita, H. 
Umetsu, and K. Ryoyama. 2011. Mouse 11beta-hydroxysteroid de-
hydrogenase type 2 for human application: homology modeling, 
structural analysis and ligand-receptor interaction. Cancer Inform. 
10: 287–295.
 46. Beck, K. R., S. Kanagaratnam, D. V. Kratschmar, J. Birk, H. 
Yamaguchi, A. W. Sailer, K. Seuwen, and A. Odermatt. 2019. 
Enzymatic interconversion of the oxysterols 7beta,25-dihydroxy-
cholesterol and 7-keto,25-hydroxycholesterol by 11beta-hydroxys-
teroid dehydrogenase type 1 and 2. J. Steroid Biochem. Mol. Biol. 
190: 19–28.
 47. Deuchar, G. A., D. McLean, P. W. F. Hadoke, D. G. Brownstein, D. 
J. Webb, J. J. Mullins, K. Chapman, J. R. Seckl, and Y. V. Kotelevtsev. 
2011. 11beta-hydroxysteroid dehydrogenase type 2 deficiency ac-
celerates atherogenesis and causes proinflammatory changes in the 
endothelium in apoe/ mice. Endocrinology. 152: 236–246.
 by guest, on Septem
ber 25, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2019/07/04/jlr.M092908.DC1
Supplemental Material can be found at:
1546 Journal of Lipid Research Volume 60, 2019
 48. Voisin, M., P. de Medina, A. Mallinger, F. Dalenc, E. Huc-Claustre, 
J. Leignadier, N. Serhan, R. Soules, G. Segala, A. Mougel, et al. 
2017. Identification of a tumor-promoter cholesterol metabolite in 
human breast cancers acting through the glucocorticoid receptor. 
Proc. Natl. Acad. Sci. USA. 114: E9346–E9355.
 49. Odermatt, A., T. Da Cunha, C. A. Penno, C. Chandsawangbhuwana, 
C. Reichert, A. Wolf, M. Dong, and M. E. Baker. 2011. Hepatic re-
duction of the secondary bile acid 7-oxolithocholic acid is mediated 
by 11beta-hydroxysteroid dehydrogenase 1. Biochem. J. 436: 621–629.
 50. Morris, D. J., and J. M. Ridlon. 2017. Glucocorticoids and gut bacteria: 
“The GALF Hypothesis” in the metagenomic era. Steroids. 125: 1–13.
 51. Yang, S., L. Jiang, and M. Z. Zhang. 2013. 11beta-Hydroxysteroid de-
hydrogenase type ii is a potential target for prevention of colorectal 
tumorigenesis. J. Oncobiomarkers. 1: 002.
 52. Rossin, D., S. Calfapietra, B. Sottero, G. Poli, and F. Biasi. 2017. 
HNE and cholesterol oxidation products in colorectal inflamma-
tion and carcinogenesis. Free Radic. Biol. Med. 111: 186–195.
 53. Willinger, T. 2019. Oxysterols in intestinal immunity and inflamma-
tion. J. Intern. Med. 285: 367–380.
 54. Ohnmacht, C. 2016. Tolerance to the intestinal microbiota medi-
ated by ROR(gammat)(+) cells. Trends Immunol. 37: 477–486.
 55. Maloy, K. J., and F. Powrie. 2011. Intestinal homeostasis and its 
breakdown in inflammatory bowel disease. Nature. 474: 298–306.
 56. Ergang, P., K. Vytackova, J. Svec, J. Bryndova, I. Miksik, and J. Pacha. 
2011. Upregulation of 11beta-hydroxysteroid dehydrogenase 1 in 
lymphoid organs during inflammation in the rat. J. Steroid Biochem. 
Mol. Biol. 126: 19–25.
 57. Hussey, M., G. Holleran, S. Smith, M. Sherlock, and D. McNamara. 
2017. The role and regulation of the 11beta-hydroxysteroid dehy-
drogenase enzyme system in patients with inflammatory bowel dis-
ease. Dig. Dis. Sci. 62: 3385–3390.
 58. Stegk, J. P., B. Ebert, H. J. Martin, and E. Maser. 2009. Expression 
profiles of human 11beta-hydroxysteroid dehydrogenases type 1 
and type 2 in inflammatory bowel diseases. Mol. Cell. Endocrinol. 301: 
104–108.
 59. Zbánková, S., J. Bryndová, P. Leden, M. Kment, A. Svec, and J. 
Pácha. 2007. 11beta-hydroxysteroid dehydrogenase 1 and 2 expres-
sion in colon from patients with ulcerative colitis. J. Gastroenterol. 
Hepatol. 22: 1019–1023.
 60. Jetten, A. M. 2009. Retinoid-related orphan receptors (RORs): criti-
cal roles in development, immunity, circadian rhythm, and cellular 
metabolism. Nucl. Recept. Signal. 7: e003.
 by guest, on Septem
ber 25, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2019/07/04/jlr.M092908.DC1
Supplemental Material can be found at:
